Innovation Challenges and Opportunities in Biopharma, MedTech, Digital Medicine, and Their Emerging Convergence: User & Patient Centric Applications in the “Pharma 3.0 Business Model Paradigm”
AbstractIn the first section of this monograph, titled “Bridging Theory and Practice for Commercialization and Innovation – a market-centered perspective for cross-industry applications”, we outlined a number of overlapping theories or models dealing with innovation. Theories, when well stated and proven, are basically statements of causality. Scientists and technologists use them all the time to predict physical or chemical phenomenon for example. However, whether or not we explicitly recognize them as such, theories also exist in the business world and can be useful as guides to behavior and decision making. These models serve as lenses through which “the world” is viewed and that enable predictions, or forecasts to be made. However, they may also act as “blinders”, limiting our ability to see that which may not fit into our existing models. As the famous statistician, George Box said in an often-repeated quote, “essentially, all models (theories) are wrong, but some are useful.”
Unless specified by prior arrangement, the author agrees to the following terms and assurances:
- For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
- I/we further give to the following assurances
- I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
- I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
- To the best of my/our knowledge, all the facts in the contribution are true and accurate;
- The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
- Nothing in the contribution is obscene or libellous;
- Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
- I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).